Gilead | chemanager-online.com - Chemistry and Life Science

Jul. 23, 2019
News & Opinions
Gilead and Galapagos in Multi-billion Linkup
Galapagos and Gilead Sciences have agreed a ten-year “multi-billion dollar collaboration” to create what they say will be a global R&D leader based in Europe and engaged in developing and commercializing breakthrough ...
Apr. 08, 2019
Topics
The Need for Innovation in Pharmaceutical Manufacturing
The global pharmaceutical industry is evolving with the rising need for novel therapies in the changing disease landscape. As a result of rising prevalence of chronic infectious diseases as well as growing cancer incidence, market needs ...
Oct. 31, 2018
News & Opinions
Gilead HIV Pill Seen to Lower new Infections
An antiviral pill taken daily by thousands of HIV-positive men in Australia has led to a “globally unprecedented” reduction in new infections, according to what is being called “the world’s first study to measure ...
Sep. 04, 2017
News & Opinions
Gilead to pay $12 Billion for Kite Pharma
US drugmaker Gilead Sciences has agreed to pay almost $12 billion to acquire compatriot Kite Pharma. Through the cash transaction, it will gain access to Car-T, Kite’s cutting-edge chimeric antigen therapy treatment for cancer. ...
Jan. 13, 2017
News & Opinions
Pharma Stocks Crash on Trump Pricing Hints
American drugmakers, who had hoped US President-Elect Donald Trump would go easier on the industry than Hillary Clinton and Bernie Sanders had promised to do, received an unexpected shock on Jan. 11. On the back of remarks made by the ...
Sep. 05, 2016
News & Opinions
Gilead Sciences Faces Another Hepatitis C Lawsuit
Gilead Sciences is once again preparing to defend itself against a challenge to its hepatitis C intellectual property. The latest lawsuit comes from the University of Minnesota which filed a claim in its district court on Aug. 29, alleging ...
Jul. 26, 2016
News & Opinions
High Drug Prices Said Pressuring US Medicare
Drugmakers who supply Medicare, the US health insurance for the elderly, are raking in billions of dollars for “pricey medications” at taxpayer expense, a report by the news agency Associated Press said provocatively, citing ...
Jul. 04, 2016
News & Opinions
FDA Approves Pill for all Hepatitis C Forms
The US Food and Drug Administration has approved Gilead Sciences’ combination pill Epclusa, the first to treat all major forms of hepatitis C. This is the latest in a series of drug approvals expected to revolutionize treatment of ...
Apr. 21, 2016
News & Opinions
Alliance Works on Low Cost Cure for Hepatitis C
Non-profit group the Drugs for Neglected Diseases initiative (DNDi) and Egyptian drug maker Pharco Pharmaceuticals have teamed up to launch a low-cost hepatitis C combination treatment. The proposed regimen, which combines drug candidate ...
Mar. 25, 2016
News & Opinions
Merck Wins Hepatitis C Patent Row with Gilead
A federal jury in California has ruled in favour of US drug maker Merck in a high-profile patent dispute with rival Gilead Sciences over sofosbuvir, the active ingredient in a new blockbuster hepatitis C treatment.

12

Register now!

The latest information directly via newsletter.

GIT Verlag